All In Biotech

Free tool

FAERS Monitor: Rolvedon

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761148 or its brand name (Rolvedon, Eflapegrastim-Xnst). Reports on generic versions are filed under their own applications.

Reports

30

Serious

16

53% of reports

Hospitalization

10

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • white blood cell count increased4
  • asthenia3
  • diarrhoea3
  • leukocytosis3
  • off label use3
  • abdominal pain2
  • accidental exposure to product2
  • bone pain2
  • constipation2
  • fatigue2
  • febrile neutropenia2
  • nausea2
  • pancytopenia2
  • thrombocytopenia2
  • vomiting2

Reports by year received

View as table
YearReports
20222
20232
202413
202510
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,129 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
leukocytosisSignal3116.239.7237
white blood cell count increasedSignal473.129.4217
pancytopenia225.16.625
bone pain223.96.324
febrile neutropenia221.15.521
accidental exposure to product213.63.613
thrombocytopenia212.53.311
constipation26.41.75
abdominal pain26.01.64
astheniaSignal35.61.97
diarrhoea33.31.13
vomiting23.00.81
off label use32.40.81
fatigue21.80.50
nausea21.80.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.